These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25368674)

  • 21. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
    Shome R; Ghosh SS
    Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.
    You KS; Yi YW; Cho J; Seong YS
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
    Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
    Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.
    Puri N; Salgia R
    J Carcinog; 2008; 7():9. PubMed ID: 19240370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
    Bonine-Summers AR; Aakre ME; Brown KA; Arteaga CL; Pietenpol JA; Moses HL; Cheng N
    Cancer Biol Ther; 2007 Apr; 6(4):561-70. PubMed ID: 17495520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
    Li Y; Huang X; Zhang J; Li Y; Ma K
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule PB; Crown J; O'Donovan N; Duffy MJ
    Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ubiquitin Mediated Degradation of EGFR by 17 β-estradiol in Triple Negative MDA-MB-231 (TNBC) Breast Cancer Cells Line.
    Khode V; Patil S; Kaveeshwar V; Ruikar K; Bargale A; E S; Patil S
    Curr Mol Med; 2022; 22(5):449-457. PubMed ID: 34376133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines.
    Lefebvre C; Pellizzari S; Bhat V; Jurcic K; Litchfield DW; Allan AL
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
    Bilir B; Kucuk O; Moreno CS
    J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
    Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
    Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.